SKYE
CBeyond Revolutionizes Obesity Treatment with Breakthrough CB1 Inhibitor Nimacimab
Cheyenne Bioscience, a cutting-edge biopharmaceutical company, has made groundbreaking strides in the treatment of obesity with its innovative CB1 inhibitor, nimacimab. According to Cheyenne's Q4 2025 conference call transcript, the company has established a promising path for nimacimab alongside existing incretin therapies, showcasing additive weight loss, encouraging durability,